Abstract:Objectives: To prospectively compare the effects on heart rate (HR) and contrast enhancement efficacy of iopamidol-370 and iodixanol-320 in contrast-enhanced, multidetector-row computed tomography (CE-MDCT).Methods: IMPACT is a multicenter, double-blind study involving 166 patients undergoing CE-MDCT of the liver (n = 121) or peripheral arteries (n = 45) randomized to receive equi-iodine doses (40 gI) of iopamidol-370 or iodixanol-320 intravenous at 4 mL/s. CE-MDCT was performed using 16-MDCT scanners according to predefined imaging protocols. HR was measured with the patient in the supine position before and continuously for 5 minutes after contrast medium administration. Mean and peak increases in HR and the proportion of subjects with predefined HR increases (>5 to <10, 10 to <15, 15 to <20, >20 bpm) were compared in the 2 populations. Liver images were assessed by 2 independent, blinded readers for contrast enhancement [Hounsfield unit (HU)], using predefined regions-of-interest during the arterial and portal-venous phase of enhancement.Results: Effects on HR: Eighty-four subjects received iopamidol-370 whereas 82 received iodixanol-320. Mean age, gender distribution, weight, total iodine dose, dose/body weight, concomitant medications and use of beta-blockers were comparable in the 2 groups. Mean baseline HR was similar in the 2 groups (iopamidol-370: 72.3 +/- 12.5 bpm; iodixanol-320: 74.5 +/- 11.9 bpm). Mean changes from baseline to peak postdose were similar in the 2 groups (8.0 +/- 9.3 bpm after iopamidol-370 and 8.4 +/- 14.7 after iodixanol-320, P = 0.72). The proportion of subjects in each group having increases of <5, >5 to <10, 10 to <15, 15 to <20, or >20 bpm was comparable (P = 0.87). Two subjects experienced postcontrast tachycardia (HR increase >70 bpm, peak HR of 146 and 164 bpm), both in the iodixanol-320 group (2.4%). Contrast Enhancement: Of the 121 patients undergoing liver CT, 60 received iopamidol-370 whereas 61 received iodixanol-320. Mean age, gender distribution, weight, total iodine dose, and dose/body weight were comparable in the 2 groups. Iopamidol-370 provided significantly higher HU values in abdominal aorta during the arterial phase of enhancement for both readers [R1: 301.3 +/- 80.2 vs. 273.6 +/- 65.9 HU, 95% confidence interval (6.1 - 56.8), P = 0.02; R2: 302.0 +/- 73.6 vs. 275.1 +/- 62.9 HU, 95% confidence interval (2.3 - 51.3), P = 0.03]. No significant difference was observed between the 2 contrast medium during the portal venous phase of enhancement.Conclusions: When the same injection rate and iodine dose is used, the effects on HR of bolus intravenous injections of iopamidol-370 and iodixanol-320 were similar. Iopamidol-370 provides significantly greater enhancement during the arterial phase and similar enhancement during the portal venous phase compared with iodixanol-320.

Comparison of 270 Versus 320 Mg I/mL of Iodixanol in 1 Image Assessment of Both Renal Arteries and Veins with Dual-Energy Spectral CT Imaging in Late Arterial Phase and Their Influence on Renal Function.

Clinical effectiveness of contrast medium injection protocols for 80-kV coronary and craniocervical CT angiography—a prospective multicenter observational study

Image Quality and Diagnostic Accuracy of Different Dosages of Iodixanol in Computed Tomography Angiography and Perfusion of Overweight Patients with Coronary Artery Stenosis: A Feasibility Study.

Hemodialysis Access CT Angiography: Feasibility of Using 80 Kv with Reduced Contrast Medium

Feasibility of low dose Iso-osmolar Contrast Media in 640-slice Volume CT Coronary Angiography

An Open Label, Prospective, Multicenter, Non-Interventional Study of Iodixanol 270 Mg I/mL for Use in Individuals Undergoing Computed Tomography Angiography in Real-World Clinical Practice.

Coronary computed tomographic angiography in coronary artery bypass grafts: comparison between low-concentration Iodixanol 270 and Iohexol 350.

Feasibilityofusing100kVptechniqueinrenalarteryCTangiographywithiodixanol(270mgI/mL)

Renal adverse effect of intravenous administration of iodixanol (270mg I/ml)

A comparison of the use of contrast media with different iodine concentrations for enhanced computed tomography

CTA of the Renal Arteries:using 100 kVp Tube Voltage and 270 mgI/ml Iodinated Contrast Medium

A Comparison of the Efficacy and Safety of Iopamidol-370 and Iodixanol-320 in Patients Undergoing Multidetector-Row Computed Tomography.

A Comparison of the Efficacy and Safety of Iopamidol-370 and Iodixanol-320 in Patients Undergoing Multidetector-Row Computed Tomography

The role of numerical model in assessing the waterway restoration for watershed management, the case of BAHR YOUSSEF, Egypt

Persistent renal enhancement after intra-arterial versus intravenous iodixanol administration.

Feasibility Research of Low Concentration Contrast Agent Iodixanol (270 mgI/mL) Combined with the Lower Tube Voltage in Coronary CTA with 640-slice Volumetric CT

Effects of contrast media with two different iodine concentrations on CT coronary angiography

Effect of Different Iodine Concentration of Contrast Media in the Enhancement of Kidney with Multislice CT

Iodine Load Reduction in Dual-Energy Spectral CT Portal Venography with Low Energy Images Combined with Adaptive Statistical Iterative Reconstruction

Application of Low Tube Voltage, Low-concentration Contrast Agent Using a 320-row CT in Coronary CT Angiography: Evaluation of Image Quality, Radiation Dose and Iodine Intake

Renal Tolerability of Iopromide and Iodixanol in 562 Renally Impaired Patients Undergoing Cardiac Catheterisation: the Direct Study